Article Information
PubMed
Print ISSN
Online ISSN
History
- Received January 23, 2003
- Accepted April 28, 2003
- Published online July 18, 2003.
Article Versions
- Earlier version (May 2, 2003 - 11:24).
- You are viewing the most recent version of this article.
Copyright & Usage
The American Society for Pharmacology and Experimental Therapeutics
Author Information
- Tracey K. Murray,
- Katherine Whalley1,
- Christine S. Robinson2,
- Mark A. Ward,
- Caroline A. Hicks3,
- David Lodge,
- Jim L. Vandergriff,
- Polly Baumbarger,
- Edward Siuda,
- Mary Gates,
- Ann M. Ogden,
- Phil Skolnick4,
- Dennis M. Zimmerman,
- Eric S. Nisenbaum,
- David Bleakman and
- Michael J. O'Neill
- Eli Lilly & Co. Ltd., Lilly Research Centre, Surrey, United Kingdom (T.K.M., K.W., C.S.R., M.A.W., C.A.H., D.L., M.J.O.); and Eli Lilly & Co., Lilly Corporate Center, Indianapolis, Indiana (J.L.V., P.B., E.S., M.G., A.M.O., P.S., D.M.Z., E.S.N., D.B.)
- Address correspondence to:
Dr. Michael J. O'Neill, Eli Lilly & Co. Ltd., Lilly Research Centre, Erl Wood Manor, Windlesham, Surrey GU20 6PH, UK. E-mail: oneill_michael_j{at}lilly.com
Statistics from Altmetric.com
Article usage
In this issue
LY503430, a Novel α-Amino-3-hydroxy-5-methylisoxazole-4-propionic Acid Receptor Potentiator with Functional, Neuroprotective and Neurotrophic Effects in Rodent Models of Parkinson's Disease
